Your browser doesn't support javascript.
loading
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial.
Shibata, Mamoru; Nihira, Atsuko; Tanji, Yuka; Ozeki, Akichika; Imagawa, Hideyuki; Komori, Mika.
Affiliation
  • Shibata M; Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan.
  • Nihira A; Department of Neurology, Nakamura Memorial Hospital, Sapporo, Japan.
  • Tanji Y; Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-Ku, Kobe, 651-0086, Japan. tanji_yuka@lilly.com.
  • Ozeki A; Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-Ku, Kobe, 651-0086, Japan.
  • Imagawa H; Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-Ku, Kobe, 651-0086, Japan.
  • Komori M; Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-Ku, Kobe, 651-0086, Japan.
Neurol Ther ; 12(6): 2007-2019, 2023 Dec.
Article in En | MEDLINE | ID: mdl-37698836
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Neurol Ther Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Neurol Ther Year: 2023 Document type: Article Affiliation country: Country of publication: